$57.68
▲ +$0.95
(+1.67%)
Vol 612K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.3B
ROE
-282.5%
Margin
-49.9%
D/E
971.11
Beta
0.35
52W
$12–$51
Wall Street Consensus
19 analysts · Apr 20267
Strong Buy
10
Buy
2
Hold
0
Sell
0
Strong Sell
89.5%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 80.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.96 | $1.58 | +$0.62 |
| Sep 2025 | $-1.47 | $0.52 | +$1.99 |
| Jun 2025 | $-1.57 | $-1.34 | +$0.23 |
| Mar 2025 | $-1.28 | $-1.28 | $0.00 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $43.1M | $27.8M | $22.3M | $76.3M | $108.2M |
| Net Income | — | -$21.8M | -$39.3M | -$38.6M | $15.1M | $49.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -282.5% | -282.5% | -282.5% | -282.5% | -282.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -173.5% | -107.7% | -107.7% | -107.7% | -49.9% | -49.9% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 971.11 |
| Current Ratio | 8.22 | 8.22 | 8.22 | 8.22 | 8.68 | 8.68 |
Key Ratios
ROA (TTM)
-21.2%
P/S (TTM)
7.92
P/B
5.7
EPS (TTM)
$-2.82
CF/Share
$-5.37
Rev Growth 3Y
+13.1%
52W High
$51.43
52W Low
$12.21
$12.21
52-Week Range
$51.43
Financial Health
Free Cash Flow
$98.0M
Net Debt
-$224.1M
Cash
$238.2M
Total Debt
$14.1M
As of Dec 31, 2025
How does ANAB compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ANAB valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
7.9
▼
38%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
5.7
▲
131%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ANAB profitability vs Biotechnology peers
ROE
-282.5%
▼
320%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-49.9%
▲
83%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-21.2%
▲
55%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
ANAB financial health vs Biotechnology peers
D/E ratio
971.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
8.7
▲
95%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.4
▼
64%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ANAB fundamentals radar
ANAB
Peer median
Industry
ANAB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ANAB vs peers: key metrics
Latest News
No related news yet